BOOM
Recent additions may not be included but will usually appear in 24 hrs or less.
| Rational | Source |
|---|---|
|
Vitamin K2 supplementation improves impaired glycemic homeostasis and insulin sensitivity for type 2 diabetes through gut microbiome and fecal metabolites. ✅
Go to Publication ✅
BMC medicine (BMC Med ) Vol: 21 Issue 1 Pages: 174 Pub: 2023 May 5 Epub: 2023 May 5 Authors Zhang Y , Liu L , Wei C , Wang X , Li R , Xu X , Zhang Y , Geng G , Dang K , Ming Z , Tao X , Xu H , Yan X , Zhang J , Hu J , Li Y , |
|
|
Vitamin K2 supplementation improves impaired glycemic homeostasis and insulin sensitivity for type 2 diabetes through gut microbiome and fecal metabolites. ✅
Go to Publication ✅
BMC medicine (BMC Med ) Vol: 21 Issue 1 Pages: 174 Pub: 2023 May 5 Epub: 2023 May 5 Authors Zhang Y , Liu L , Wei C , Wang X , Li R , Xu X , Zhang Y , Geng G , Dang K , Ming Z , Tao X , Xu H , Yan X , Zhang J , Hu J , Li Y , |
|
|
Vitamin K2 supplementation improves impaired glycemic homeostasis and insulin sensitivity for type 2 diabetes through gut microbiome and fecal metabolites. ✅
Go to Publication ✅
BMC medicine (BMC Med ) Vol: 21 Issue 1 Pages: 174 Pub: 2023 May 5 Epub: 2023 May 5 Authors Zhang Y , Liu L , Wei C , Wang X , Li R , Xu X , Zhang Y , Geng G , Dang K , Ming Z , Tao X , Xu H , Yan X , Zhang J , Hu J , Li Y , |
|
|
Vitamin K2 supplementation improves impaired glycemic homeostasis and insulin sensitivity for type 2 diabetes through gut microbiome and fecal metabolites. ✅
Go to Publication ✅
BMC medicine (BMC Med ) Vol: 21 Issue 1 Pages: 174 Pub: 2023 May 5 Epub: 2023 May 5 Authors Zhang Y , Liu L , Wei C , Wang X , Li R , Xu X , Zhang Y , Geng G , Dang K , Ming Z , Tao X , Xu H , Yan X , Zhang J , Hu J , Li Y , |
|
|
Menaquinone analogs inhibit growth of bacterial pathogens. ✅
Go to Publication ✅
Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother ) Vol: 57 Issue 11 Pages: 5432-7 Pub: 2013 Nov Epub: 2013 Aug 19 Authors Schlievert PM , Merriman JA , Salgado-Pabón W , Mueller EA , Spaulding AR , Vu BG , Chuang-Smith ON , Kohler PL , Kirby JR , |
|
|
Phylloquinone is preferable over menadione as a growth factor for Porphyromonas gingivalis. ✅
Go to Publication ✅
Journal of oral biosciences (J Oral Biosci ) Vol: 65 Issue 4 Pages: 273-279 Pub: 2023 Dec Epub: 2023 Sep 1 Authors Saiki K , Urano-Tashiro Y , Yamanaka Y , Takahashi Y , |
|
|
Phylloquinone is preferable over menadione as a growth factor for Porphyromonas gingivalis. ✅
Go to Publication ✅
Journal of oral biosciences (J Oral Biosci ) Vol: 65 Issue 4 Pages: 273-279 Pub: 2023 Dec Epub: 2023 Sep 1 Authors Saiki K , Urano-Tashiro Y , Yamanaka Y , Takahashi Y , |
|
|
Association of Poor Vitamin K Status with Inflammation and Gut Microbiota in Hemodialysis Patients: A Cross-Sectional Study. ✅
Go to Publication ✅
The Journal of nutritional biochemistry (J Nutr Biochem ) Vol: Issue Pages: 110139 Pub: 2025 Oct 4 Epub: 2025 Oct 4 Authors Lima LS , Ribeiro M , Cardozo LFMF , Bittner R , Ribeiro-Alves M , Schultz J , Rosado AS , Leite PEC , Nakao LS , Schurgers LJ , Mafra D , |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
